Table 1.
HCV JFH-1 neutralization assay
| Genotype | Nba | M/Fb ratio | Age (yr) | HCV RNAc (log IU/mL) | Mean ± SDd | Rangee |
| 1a | 11 | 7/4 | 43 ± 6 | 5.90 ± 0.6 | 2.046 ± 0.671 | 0.926 – 3.121 |
| 1b | 11 | 5/6 | 48 ± 16 | 6.16 ± 0.5 | 1.747 ± 0.462 | 0.934 – 2.356 |
| 2 | 11 | 9/2 | 63 ± 12 | 5.50 ± 0.9 | 2.128 ± 0.365 | 1.486 – 2.742 |
| 3 | 12 | 8/4 | 40 ± 11 | 5.66 ± 0.6 | 2.148 ± 0.478 | 1.326 – 2.977 |
| 4 | 10 | 4/6 | 45 ± 11 | 6.07 ± 0.7 | 1.786 ± 0.236 | 1.453 – 2.152 |
| 5 | 2 | 1/1 | 66 ± 14 | 6.06 ± 0.6 | 1.755 ± 0.005 | nd |
| all | 57 | 34/23 | 48 ± 15 | 5.83 ± 0.7 | 1.970 ± 0.491 | 0.934 – 3.121 |
a Number of samples tested.
b F, female; M, male.
c HCV RNA measured using the Amplicor HCV Monitor assay, version 2.0 (Roche Diagnostics, Meylan, France) and expressed in log equivalents of IU/mL.
d Neutralizing anti-HCV antibodies titers expressed in log units; mean ± SD
e Range of neutralizing anti-HCV antibodies titers, expressed in log units